挪威 - 挪威文 - Statens legemiddelverk

abbvie as - leuprorelinacetat - pulver og væske til injeksjonsvæske, suspensjon i tokammersprøyte - 3.75 mg

挪威 - 挪威文 - Statens legemiddelverk

abbvie as - leuprorelinacetat - pulver og væske til injeksjonsvæske, suspensjon i tokammersprøyte - 30 mg

挪威 - 挪威文 - Statens legemiddelverk

2care4 aps - leuprorelinacetat - pulver og væske til injeksjonsvæske, suspensjon i tokammersprøyte - 3.75 mg

挪威 - 挪威文 - Statens legemiddelverk

2care4 aps - leuprorelinacetat - pulver og væske til injeksjonsvæske, suspensjon i tokammersprøyte - 11.25 mg

挪威 - 挪威文 - Statens legemiddelverk

orifarm generics a/s - vinorelbintartrat - kapsel, myk - 30 mg

挪威 - 挪威文 - Statens legemiddelverk

orifarm generics a/s - vinorelbintartrat - kapsel, myk - 20 mg

欧盟 - 挪威文 - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - bryst neoplasms - antineoplastiske midler - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

欧盟 - 挪威文 - EMA (European Medicines Agency)

accord healthcare s.l.u. - cabazitaxel - prostatic neoplasmer, kastrering-resistant - antineoplastiske midler - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

欧盟 - 挪威文 - EMA (European Medicines Agency)

accord healthcare s.l.u. - abirateronacetat - prostata neoplasmer - endokrin terapi - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

欧盟 - 挪威文 - EMA (European Medicines Agency)

mylan ireland limited - abirateronacetat - prostata neoplasmer - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.